colon cancer
Conditions
Interventions
None listed
Sponsors
Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet the criteria below will be enrolled. Gender, admission/outpatient clinic will not be assessed. 1) Patients who undergo total colonoscopy examination 2) Patients aged more than 20 years when informed consent is obtained. 3) Patients who give the informed consent. Colon cancer 100 patients and non-colon cancer 100 cases will be enrolled.
Exclusion criteria
Exclusion criteria: The patients who meet any of the criteria below will be excluded. 1) Patients who have been diagnosed with malignancy within 5 year of the date of the informed consent. 2) Patients who have been treated with interferon treatment within one year of the date of the informed consent, or is currently undergoing interferon treatment. 3) Patients who have been treated with adrenal hormone (except for local treatment) or biological drug (etc. infliximab) within 6 months. 4) Patients who have been treated with anti-cancer drug within 6 months of the informred consent. 5) Patients who are infected with hepatitis B, hepatitis C or other infectious diseases. 6) Patients who have been diagnosed with irritable bowel syndrome, ulcerative colitis, and Crohn disease. 7)Patients, who are judged to be not appropriate for entry by the trial responsible (collaborative) doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity, specificity | — |
Secondary
| Measure | Time frame |
|---|---|
| positive predictive value and negative predictive value of stool occult blood test. positive predictive value and negative predictive value of blood mRNA test. | — |
Countries
Japan
Contacts
Public ContactYoshio Sakai
Kanazawa University school of medicine
Outcome results
None listed